Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039.

Keyphrases

metastatic colorectal cancer
circulating tumor
wild type
cell free
clinical trial
circulating tumor cells
protein kinase
tyrosine kinase
electronic health record
big data
single molecule
artificial intelligence
open label